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Abstract
The epidemiological status of HCV in Europe, and in particular in Mediterranean countries, is continuously evolving.
The genotype distribution is related to improvement of healthcare conditions, expansion of intravenous drug use
and immigration. We review and characterize the epidemiology of the distribution of HCV genotypes within
Calabria, an area of Southern Italy. We focus on the pattern of distinct HCV genotype changes over the last
16 years; particularly subtype 1b and genotype 4. We collected data by evaluating a hospital-based cohort of
chronic hepatitis C patients; in addition, we report an update including new patients enrolled during last eight
months.
Introduction
Hepatitis C virus (HCV) triggers worldwide chronic liver
diseases, as cirrhosis and hepatocellular carcinoma
(HCC). HCV infection represents the most important
cause of liver transplantation in developed countries.
Despite the decline of the viral transmission rates, due
to eradication of transfusion-associated infections and
improvement in health-care-related standards, HCV-
related morbidity and mortality continue to rise and, due
to slow disease progression, many patients are still at risk
to progress to severe liver diseases [1]. For this reason
prevention of HCV infections as well as improved knowl-
edge of HCV infection epidemiology are particularly
noteworthy.
HCV genotyping is an important approach in the man-
agement of HCV RNA positive patients and it is useful to
understand the epidemiology of the virus with respect to
the demographic characteristics of patients, liver disease
grade, risk factors and source of infection. Genotyping has
also been used to found HCV geographical distribution:
subtype 1b is spreading worldwide, subtype 3a is clustering
in Europe and North America and genotype 4 appears
endemic in Middle East and Central Africa. It is already
known that the prevalence of HCV, in a particular area,
can be unstable and HCV changing pattern occurs
because of several factors, as high rates of mutation in
viral genome, drug pressure and migration of infected peo-
ple to countries where a more sensitive population is
established.
On this HCV changing pattern, surveillance studies
have been carried out in several European regions [2,3].
Since 1997, our group studied distribution of HCV
genotypes within Calabria, a region of Southern Italy, by
evaluating a hospital-based cohort of chronic hepatitis C
patients. This mini-review summarizes published data
on the epidemiology of HCV within this area, focusing
on the pattern of distinct HCV genotype changes over
the last 16 years, particularly subtype 1b and genotype
4. In addition, an update of the last eight months will be
addressed.
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HCV spread in the Mediterranean countries of
Europe
In Europe, the epidemiology of HCV infection is rapidly
changing and prevalence, as well as risk factors and geno-
type distribution exhibit significant geographic and tem-
poral differences. In Northern and Central Europe the
HCV prevalence is ranging from 0.2% (in the Netherlands)
to 1.2% (in France) [2], virus is mainly transmitted by
intravenous drug use (IDU) and the most prevalent infec-
tions are found among patients 30–50 years old. In coun-
tries of the Mediterranean area of Europe the overall
prevalence ranges between 2.5% and 3.5% [2], spread via
blood products as well as IDU-related infections have
been determined. Most importantly, immigration is lead-
ing to changes in HCV epidemiology and in the distribu-
tion of HCV genotypes. In Spain HCV prevalence is
among the highest in Europe, with high rate of genotype 3
(mainly among IDUs) while the increasing rate of geno-
type 4 has been reported to be linked to IDU and immi-
gration [4,5].
Differences in prevalence of HCV infection have been
observed in Turkey, where higher rates are reported in
regions near the Black Sea when compared with other
areas; the genotype 1b was ranging between 75 and 90% in
chronic infected patients [1,6,7]. In Turkey, the non-hospi-
talized childbirth or invasive and poor-hygiene standard
medical procedures may increase the risk of transmission
of HCV [1]. In Greece, another country in the Mediterra-
nean region of Europe, the prevalence of the disease is
high (6–10%) in some isolated areas and it is mainly due
to unsafe parenteral injections or invasive medical proce-
dures. Genotype 1 is predominant among chronically
infected people, genotype 3 is rising and 15% of infections
are caused by genotype 4 [8,9].
In Italy, the HCV epidemiology has some specificity. In a
HCV seroprevalence and molecular epidemiology study,
performed in a sample of the Italian general population,
Ansaldi et al., [10] showed a north–south prevalence gra-
dient and confirmed that Central and Southern Italy are
hyper endemic areas. In this study HCV subtype 1b was
the most prevalent in all geographical areas followed by
subtypes 2c, 4a/4d, 3a and 1a. The prevalence of subtype
1b increased with age.
Overall, risk factors are related to hospital-based
transmission, healthcare-related or IDU transmission
and, concerning age distribution, a high prevalence of
HCV in the elderly has been established. Different stu-
dies reported on the genotype distribution of HCV in
Italy [11-15]. Genotype 1b appeared to be the most fre-
quent type of infection [13-15] followed by genotype 2,
which is more common in Italy than in other parts of
Europe. Likewise, in a small epidemiological study, car-
ried out in a Southern Italian town, HCV subtype 2a
has been reported to be predominant with respect to
subtype 1b [11]. Changes in the prevalence of HCV
genotypes among Italian injection drug users, in rela-
tion to the time of infection, have been reported [12],
namely a decline in genotype 3 has been observed,
while genotype 4 has become more frequent. The pre-
valence of HCV type 4 increased in Southern [16], and
Central Italy [14]. Genotype 5 and 6 HCV were rarely
found as well as mixed infections with more genotypes
[1].
HCV in Calabria region: epidemiological features
In our first investigation we report data on changes in
the prevalence of hepatitis C virus genotype 4 in Calab-
ria, Southern Italy. In particular we evaluated prevalence
of circulating HCV genotypes, as well as relationships
between genotype, sex and age in sera from 3273 HCV-
positive patients collected from January 1997 until
February 2001 [16].
The main findings on genotype distribution showed
that HCV 1b was the most common subtype (1744
cases, 53.3%) followed by 2a/2c (857 cases, 26.2%) and
both were associated with older age. This distribution
was similar to other studies regarding the prevalence of
HCV genotypes in Italy and Western Europe.
Genotype 4 was the fifth most prevalent genotype
observed, just after 3a and 1a subtypes. Analyzing the
distribution of the HCV genotype 4 during three consecu-
tive periods of 17, 19 and 13 months, within the full obser-
vation period, we reported an early increase (January
1997–May 1998) of the genotype 4 (3.3% versus 1.3%),in
comparison to prevalence findings previously observed by
Guadagnino et al., [17]. Data obtained from serum sam-
ples, collected from June 1998 until December 1999 and
from January 2000–February 2001, indicated a further
increase in prevalence of genotype 4 (3.7% and 4.7%
respectively).
Therefore, on HCV positive sera collected from January
1997 until February 2001, we verified a fourfold increased
prevalence of HCV genotype 4. While in this period other
authors found type 4 to be related to IDU in younger indi-
viduals [18], by contrast our data showed that spreading of
genotype 4 in the Calabria region was associated with
older age, when compared to genotype 3a and 1a, and
associated with a younger group of patients when com-
pared with genotype 1b. Moreover, HCV genotype 4-
infected patients denied having traveled to endemic areas
and most of them lived in rural areas. We assumed that
such an increase could be partially due to previous under-
valuation of the real prevalence of genotype 4 in the
Calabria. Moreover, we hypothesized that this HCV geno-
type could be endemic in some restricted and isolated
areas of Calabria.
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Recently we updated data on the distribution of HCV
genotypes, by evaluating a hospital-based cohort of 2153
chronic hepatitis C patients, collected prospectively among
subjects attending University Hospital of Catanzaro,
Calabria, Southern Italy [19]. The rates of HCV genotypes
during two consecutive periods, from 2001 to 2005 and
from 2006 to 2011, according to age and gender were con-
sidered. Concerning the eleven-year period of observation,
subtype 1b was predominant (49.2%), followed by subtype
2a/2c, genotypes 3 and 4, with a rate of 22.4%, 7.4% and
6.2% respectively.
Still at present subtype 1b is the most common HCV
type associated with risk factors such as blood/blood deri-
vatives transfusion and surgical procedures. Subtype 1b-
infected patients are >65 years old, accordingly with
Ansaldi et al., who reported a transmission pattern found
in adults older than 60 years, due to health care-related
practices in the past and characterized by subtypes 1b and
2c infections [10]. As in other European reports, our data
show that 1b prevalence decreased over the past eleven
years and this finding is mainly due to the improved health
standards that reduced HCV transmission.
When data of the two consecutive periods were exam-
ined, a higher percentage of HCV infection in >65 age
group (33.7% versus 41.2%) was observed. Between 2001
and 2005, the distribution of subtype 1b was similar in 56
- 65 and >65 age groups, while between 2006 and 2011
data showed an increased distribution in >65 age group
with respect to 56 - 65 age group. Interestingly, during the
2006–2011 period HCV genotype 4 was mostly present in
patients 56 - 65 years old (31.6%), while two different
peaks, during the 2006 – 2011 period, were observed:
27.6% among the 36 - 45 years old and 24.1% in patients
over 65 years old.
Therefore, during the 2006 - 2011 period, statistical ana-
lysis of HCV patient age, stratified by genotypes, showed a
slight but significant increase in the median age of subtype
1b, subtype 2a/2c and genotype 3 HCV infected subjects,
while genotype 4 patients exhibited a decrease in the med-
ian age during the same period studied.
Genotype 4 is to date the fourth prevalent genotype in
our area and the observation regarding the shift of the
highest prevalence of genotype 4 towards younger age
group (36 - 45) during 2006 - 2011, sounds as a challenge
for epidemiologists. Probably this trend could be related to
increased sexual risk behavior.
Update of HCV epidemiology in Calabria
The update of our epidemiology investigation includes
the new subjects enrolled as a hospital – based cohort
of HCV-infected patients during last eight months. The
age of patients with genotype/subtype 3 was significantly
lower than age of subjects with genotypes/subtypes 1b
(p < 0.05 Tukey post-hoc test). Also the age of patients
with genotype/subtype 2a/2c, 4 and 1 was higher than
the age of subjects with genotype 3, without a statistical
significance (Figure 1). Dealing with gender distribution
of genotypes/subtypes HCV we found a significant (p <
0.05 by c2 test) predominance of females among the 2a/
2c –positive subjects, by contrast the male gender was
significantly associated with genotype 3 (p < 0.05 by c2
test). Regarding the viral load the subtypes 2a/2c and 1a
shared the highest values; the genotypes/subtypes 1b, 1
and 3 exhibit the medium values, and genotypes 4 and 2
showed a lower amount of viral load (Table 1).
Conclusion
HCV epidemiology shows a high variability across Medi-
terranean countries of Europe and Italy. The evaluation of
chronic HCV prevalence, genotype distribution and risk
factors for transmission, represent a great challenge, which
will pay off in achievement of efficient measures for hepa-
titis C prevention. Nation-specific strategies could be
applied in different countries to decrease spreading of
HCV infection. The most representative change in HCV
genotype prevalence, observed in our region, has been
reported to be an increase in genotype 4. Appropriated
interventions are warranted to control genotype 4 epi-
demics because this genotype is associated with a great
risks of complications (cirrhosis and HCC) [20] and a
poor response to standard treatment. Such interventions
can now be difficult because the ways of transmission are
expanding, including not only IDU, but also, probably,
sexual risk behaviors.
Figure 1 Box plot of genotypes 1b, 2a/2c, 3, 4 and 1 distribution by
HCV patients age in the January-August 2012 period. * p < 0.05 vs.
genotype 1b.
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Table 1 HCV genotypes/subtypes distribution, gender and viral load of 67 patients from January to August 2012.
HCV genotypes/ subtypes No. of isolates Percentage (%) Gender P value Log10 HCV-RNA (UI/ml)
Mean± SEM
Male (%) Female (%)
1 7 10.5 2 28.6 5 71.4 > 0.05 6.6 ± 6.2
1b 29 43.3 19 65.5 10 34.5 > 0.05 6.7 ± 6.4
1a 4 5.9 3 75.0 1 25.0 > 0.05 7.0 ± 6.6
2 1 1.5 0 0.0 1 100.0 > 0.05 3.3 ± 0.0
2a/2c 17 25.4 6 35.3 11 64.7 < 0.05 7.1 ± 6.7
3 4 5.9 4 100.0 0 0.0 < 0.05 3.7 ± 6.3
4 5 7.5 3 60.0 2 40.0 > 0.05 3.2 ± 5.9
Total 67 100 37 55.2 30 44.8 3.9 ± 6.3
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